Related references
Note: Only part of the references are listed.Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology
Rashmi R. Shah
DRUG SAFETY (2019)
Progressive diffuse large B-cell lymphoma with TP53 gene mutation treated with chidamide-based chemotherapy
Qing Li et al.
IMMUNOTHERAPY (2019)
Lower expression of Bax predicts poor clinical outcome in patients with glioma after curative resection and radiotherapy/chemotherapy
Pei-Guo Wang et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC
Ningning Zhang et al.
JOURNAL OF CANCER (2019)
The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy
David Briere et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat
Chiara Zagni et al.
MEDICINAL RESEARCH REVIEWS (2017)
Chidamide in the treatment of peripheral T-cell lymphoma
Thomas S. Chan et al.
ONCOTARGETS AND THERAPY (2017)
The HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo
Annarita Scialdone et al.
ONCOTARGET (2017)
Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy
Shuai Gao et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2017)
Methyltransferase SETD2-Mediated Methylation of STAT1 Is Critical for Interferon Antiviral Activity
Kun Chen et al.
CELL (2017)
Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT
Juliane Paul et al.
CANCER CELL (2017)
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research
Grzegorz S. Nowakowski et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Activation of integrin α5 mediated by flow requires its translocation to membrane lipid rafts in vascular endothelial cells
Xiaoli Sun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Diffuse large B-cell lymphoma: R-CHOP failure-what to do?
Bertrand Coiffier et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research
Grzegorz S. Nowakowski et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China
Xianping Lu et al.
INTRACTABLE & RARE DISEASES RESEARCH (2016)
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
Robert Chen et al.
HAEMATOLOGICA (2015)
Histone Deacetylase Inhibitors: A Review on Class-I Specific Inhibition
Jagannath Behera et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2015)
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
Robert Chen et al.
HAEMATOLOGICA (2015)
Interaction of membrane/lipid rafts with the cytoskeleton: Impact on signaling and function Membrane/lipid rafts, mediators of cytoskeletal arrangement and cell signaling
Brian P. Head et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2014)
Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia
Li Jia et al.
BLOOD (2014)
Postulated Mechanisms of Resistance of B-Cell Non-Hodgkin Lymphoma to Rituximab Treatment Regimens: Strategies to Overcome Resistance
Benjamin Bonavida
SEMINARS IN ONCOLOGY (2014)
Management of relapsed-refractory diffuse large B cell lymphoma
Lalit S. Raut et al.
SOUTH ASIAN JOURNAL OF CANCER (2014)
Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
Bjoern Chapuy et al.
CANCER CELL (2013)
Expression of FOXP3, CD68, and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lymphoma Is Predictive of Outcome
Paul Greaves et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity
Zhi-Qiang Ning et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas
Mei Dong et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Comparison of CD20 expression in B-cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment
Hiroaki Miyoshi et al.
CANCER SCIENCE (2012)
CD20 gene deletion causes a CD20-negative relapse in diffuse large B-cell lymphoma
Tsuyoshi Nakamaki et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
A unique chromatin signature uncovers early developmental enhancers in humans
Alvaro Rada-Iglesias et al.
NATURE (2011)
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
Stephen A. Beers et al.
BLOOD (2010)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao et al.
CELL (2010)
Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
Sean J. Whittaker et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells
R. Shimizu et al.
LEUKEMIA (2010)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
Histone H3K27ac separates active from poised enhancers and predicts developmental state
Menno P. Creyghton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Chemical mechanisms of histone lysine and arginine modifications
Brian C. Smith et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2009)
Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance
Junji Hiraga et al.
BLOOD (2009)
Phosphotyrosine protein dynamics in cell membrane rafts of sphingosine-1-phosphate-stimulated human endothelium: Role in barrier enhancement
Jing Zhao et al.
CELLULAR SIGNALLING (2009)
Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels
Myron S. Czuczman et al.
CLINICAL CANCER RESEARCH (2008)
Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis
Verena Brune et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Stromal Gene Signatures in Large-B-Cell Lymphomas
G. Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Histone deacetylases and cancer
M. A. Glozak et al.
ONCOGENE (2007)
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents
Jing Deng et al.
CANCER CELL (2007)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia
Michael E. Williams et al.
JOURNAL OF IMMUNOLOGY (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Integrin-dependent interaction of lipid rafts with the actin cytoskeleton in activated human platelets
S Bodin et al.
JOURNAL OF CELL SCIENCE (2005)
X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
RL Camp et al.
CLINICAL CANCER RESEARCH (2004)
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia
I Jilani et al.
BLOOD (2003)
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
MR Smith
ONCOGENE (2003)
Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review
GA Kennedy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
CD20-mediated apoptosis: signalling through lipid rafts
JP Deans et al.
IMMUNOLOGY (2002)
Share Paper
